Exelixis News and Activities
Presence
Exelixis develops and sells cancer medicines and related therapies. It serves hospitals, clinics, and healthcare providers that treat people with serious diseases.
Exelixis products and services overview:
- Cancer therapies
- Drug discovery
- Clinical development
- Biotech licensing
Revenue: ~$2 billion
Employees: 1,100
Headquarters: Alameda, United States (USA)
Exelixis is one of the...
Exelixis is a company listed under the stock ticker EXEL (US).
Executives
View the org chart displaying its 18 main executives
Most searched biographies at Exelixis
- Michael Morrissey, Director, Chief Executive Officer and President
- Stelios Papadopoulos, Chairman of the Board
- Jack Wyszomierski, Director
Popular executive movements at Exelixis
- Jeffrey Hessekiel, Executive Vice President, General Counsel and Secretary, has left the company (posted on November 10 2025).
- Brenda Hefti, who was Senior Vice President, Intellectual Property and Licensing, is promoted to General Counsel (posted on November 10 2025).
Create your alert
to follow the executive moves at Exelixis.
Biotechnology
Exelixis has 2,405 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).
Popular M&A news in Biotechnology
- IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).
- NewLimit has just announced a $435 Million fundraising (posted on June 3 2026).
- Rallybio and Avenzo Therapeutics have announced they will merge (posted on June 1 2026)..
Popular contacts in Biotechnology
News
Press releases by Exelixis
- Exelixis to Release Second Quarter 2022 Financial Results on Tuesday, August 9, 2022 | Exelixis, Inc.
- Exelixis Announces Cabozantinib in Combination with Nivolumab and Ipilimumab Significantly Improved Progression-Free Survival in Phase 3 COSMIC-313 Pivotal Trial in Patients with Previously Untreated Advanced Kidney Cancer | Exelixis, Inc.
- Exelixis and Ryvu Therapeutics Establish Exclusive License Agreement to Develop Novel STING Agonist-Based Targeted Cancer Therapies | Exelixis, Inc.
- Exelixis to Webcast Fireside Chat as Part of the William Blair Biotech Focus Conference | Exelixis, Inc.
- Exelixis Announces Initiation of the STELLAR-303 Phase 3 Pivotal Trial Evaluating XL092 in Patients with Metastatic Colorectal Cancer | Exelixis, Inc.
- Exelixis and BioInvent Establish Exclusive Option and License Agreement to Develop Novel Antibody-Based Immuno-Oncology Therapies | Exelixis, Inc.
- Exelixis To Webcast Fireside Chats as Part of Investor Conferences in June | Exelixis, Inc.
- Exelixis Announces Detailed Results from Urothelial Carcinoma and Non-Small Cell Lung Cancer Cohorts of the COSMIC-021 Trial at ASCO 2022 | Exelixis, Inc.
- Exelixis Announces Results from Phase 2 Trial of Cabozantinib in Combination with Pembrolizumab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma at ASCO 2022 | Exelixis, Inc.
- Exelixis Announces First Quarter 2022 Financial Results and Provides Corporate Update | Exelixis, Inc.
- View more press releases Close
Social media about Exelixis
- Exelixis on Wikipedia, Google News & Yahoo Finance
- Exelixis on LinkedIn, X (Twitter) & YouTube
